Simultaneous action of the flavonoid quercetin on cytochrome p450 (cyp) 1a2, cyp2a6, n-acetyltransferase and xanthine oxidase activity in healthy volunteers

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 8, 2009, Pages 828-833

  Chen, Yao ^a   Xiao, Peng ^a   Ou Yang, Dong Sheng ^a   Fan, Lan ^a   Guo, Dong ^a   Wang, Yi Nan ^a   Han, Yang ^a   Tu, Jiang Hua ^a   Zhou, Gan ^a   Huang, Yuan Fei ^a   Zhou, Hong Hao ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

CYP1A2; CYP2A6; N acetyltransferase; Quercetin; Xanthine oxidase

Indexed keywords

1 METHYLURATE; 1 METHYLXANTHINE; 1,7 DIMETHYLURATE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; PARAXANTHINE; QUERCETIN; UNCLASSIFIED DRUG; URATE; XANTHINE OXIDASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NORMAL HUMAN; URINARY EXCRETION;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; QUERCETIN; TIME FACTORS; XANTHINE OXIDASE; YOUNG ADULT;

EID: 68549120981     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05158.x     Document Type: Article

References (24)

1. de Vries JH, Hollman PC, Meyboom S et al. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am. J. Clin. Nutr. 1998 68 : 60 5.
2. Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999 340 : 715 22.
3. Gross M, Pfeiffer M, Martini M, Campbell D, Slavin J, Potter J. The quantitation of metabolites of quercetin flavonols in human urine. Cancer Epidemiol. Biomarkers Prev. 1996 5 : 711 20.
4. Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam. Appl. Toxicol. 1992 19 : 423 31.
5. Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther. 2005 4 : 949 55.
6. Pignatelli P, Pulcinelli FM, Celestini A et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am. J. Clin. Nutr. 2000 72 : 1150 5.
7. Yeh SL, Wu SH. Effects of quercetin on beta-apo-8′-carotenal- induced DNA damage and cytochrome P1A2 expression in A549 cells. Chem. Biol. Interact. 2006 163 : 199 206.
8. Lin SY, Tsai SJ, Wang LH, Wu MF, Lee H. Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells. Role of COX-2. Nutr. Cancer 2002 44 : 95 101.
9. Desbrow B, Hughes R, Leveritt M, Scheelings P. An examination of consumer exposure to caffeine from retail coffee outlets. Food Chem. Toxicol. 2007 45 : 1588 92.
10. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998 709 : 27 34.
11. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr. 2007 21 : 190 200.
12. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 1987 42 : 157 65.
13. Kang IH, Kim HJ, Oh H, Park YI, Dong MS. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat. Res. 2004 545 : 37 47.
14. Choi JS, Li X. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int. J. Pharm. 2005 297 : 1 8.
15. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 2006 313 : 144 9.
16. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci. 2002 72 : 227 35.
17. Dudka J, Jodynis-Liebert J, Korobowicz E et al. Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: An in vitro study. Basic Clin. Pharmacol. Toxicol. 2005 97 : 74 9.
18. Rahden-Staron I, Czeczot H, Szumilo M. Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin. Mutat. Res. 2001 498 : 57 66.
19. Wong P, Villeneuve G, Tessier V et al. Stability of 5-acetamido-6- formylamino-3-methyluracil in buffers and urine. J. Pharmaceut. Biomed. 2002 28 : 693 700.
20. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin. Pharmacol. Ther. 1983 33 : 591 602.
21. 2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992 2 : 116 27.
22. Bendriss EK, Markoglou N, Wainer IW. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J. Chromatogr. B Biomed. Sci. Appl. 2000 746 : 331 8.
23. Caubet MS, Elbast W, Dubuc MC, Brazier JL. Analysis of urinary caffeine metabolites by HPLC-DAD. The use of metabolic ratios to assess CYP1A2 enzyme activity. J. Pharm. Biomed. Anal. 2002 27 : 261 70.
24. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses. Antimicrob. Agents Chemother. 2005 49 : 1733 8.